PERSANTIN PERSANTIN PERSANTIN DAMOPRES DAMOPRES

Dose: 75 to 100 mg
Single Dose: 88 (87.5)
Frequency: 6 hourly
Route: PO
Instructions:

Dose: 1.25 mg/kg
Single Dose: 1.2 (1.25)
Frequency: 6 hourly
Route: Oral
Instructions: -

Dose: 5 mg/kg
Single Dose: 5 (5)
Frequency: 6 hourly
Route: Oral
Instructions:

. It is of Synthetic origin and belongs to Piperidinopyrimidine. It belongs to Phosphodiesterase inhibitor pharmacological group on the basis of mechanism of action and also classified in Hematological Agents and Antiplatelet Agent pharmacological group.The Molecular Weight of Dipyridamole is 504.60. Its pKa is 6.4.

Dipyridamole is contraindicated in conditions like Bleeding disorders.

The severe or irreversible adverse effects of Dipyridamole, which give rise to further complications include Angina.Dipyridamole produces potentially life-threatening effects which include Hemorrhage, Coronary steel, Hemorrhage. which are responsible for the discontinuation of Dipyridamole therapy.The signs and symptoms that are produced after the acute overdosage of Dipyridamole include Flushing.The symptomatic adverse reactions produced by Dipyridamole are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Dizziness, Headache, Nausea, Vomiting, Diarrhea, Pruritus, Skin rash, Facial flushing, Syncope, GI disturbance, dizziness, Fainting.

Dipyridamole is primarily indicated in conditions like Ischemic stroke prophylaxis, Secondary prevention of ischaemic stroke and tias, Transient ischemic attacks prophylaxis, and can also be given in adjunctive therapy as an alternative drug of choice in Analgesia and suppression of respiratory activity.

Dipyridamole is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAdenosineEffect of adenosine enhanced and extended by dipyridamole (Important, Risk of toxicity).AspirinBenorylateCaffeineCertoparinCholine Magnesium TrisalicylateDalteparinEnoxaparinFludarabineHeparin (Na) and Heparin (Cl)Nadroparin (Ca)Concurrent use may increase the risk of hemorrhage.ReteplaseConcurrent use may increase the risk of bleeding.Riociguatcause hypotensionMajorcontraindicatedSalicylic AcidTenecteplaseDipyridamole may increase the risk of bleeding if administered prior to, during or after Tenecteplase therapy.Tiaprofenic AcidDipyridamole can cause an increased risk of bleeding. Tinzaparin SodiumConcurrent use may increase the risk of bleeding.If coadministration is essential, close clinical and laboratory monitoring of these patients is advised.Warfarin (Na) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Laboratory tests involving fluorescence or nephelometry measurements

Drug should not be given to Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store at room temperature. Do not Freeze. Protect from Sunlight. Tab Store Below 40°C. Protect from Sunlight and Moisture.

Dipyridamole should not be used in patients with hypotension unstable angina, aorticstenosis, recent myolar dial infarction because it will produced peripheral vasodilation. It should be used with caution in patient with asthma. It is classified as pregnancy category B and should be used with caution in pregnancy only if clearly needed.